Advertisement
JNJ vs NVS
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- JNJ has maintained relative stability in recent market activity amid positive pipeline updates in oncology and medical devices, while NVS experienced a sharp decline following late-stage trial setbacks.
- Both companies operate in the pharmaceuticals sector with diversified portfolios spanning innovative medicines and established products, though JNJ benefits from broader exposure across pharmaceuticals and MedTech.
- Recent weeks highlighted contrasting momentum: JNJ advanced select regulatory milestones, whereas NVS faced investor scrutiny over acquisition-related pipeline risks.
- Market positioning shows JNJ with a larger capitalization and defensive characteristics, compared to NVS’s focus on targeted therapies amid volatility.
- Sector sentiment remains influenced by clinical data readouts, with both stocks reflecting broader healthcare trends in innovation and regulatory outcomes.
- Relative performance underscores trade-offs between stability in established franchises and higher-risk growth bets in emerging modalities.
Introduction
Johnson & Johnson (JNJ) and Novartis (NVS) represent two leading global pharmaceutical companies with substantial market presence and extensive research pipelines. This comparison examines their recent stock behavior, business profiles, and key differentiators in the current environment. Institutional investors, portfolio managers, and traders evaluating healthcare sector exposure may find the analysis relevant for assessing relative positioning, risk profiles, and potential catalysts. The focus remains on verifiable developments and observable metrics rather than forward projections.
JNJ Overview and Recent Performance
Johnson & Johnson operates across pharmaceuticals, MedTech, and consumer health segments, with a focus on oncology, immunology, and surgical innovations. In recent market activity, the stock demonstrated resilience, supported by regulatory progress such as positive survival data for RYBREVANT in lung cancer and CE marking for advanced contact lenses. Broader pipeline highlights included neuropsychiatry presentations and ongoing MedTech advancements. Performance reflected steady interest amid healthcare sector movements, with the company maintaining a significant market capitalization near $640 billion. Sentiment benefited from consistent operational execution and diversified revenue streams, contributing to relative outperformance versus more volatile peers in the period.
NVS Overview and Recent Performance
Novartis concentrates on innovative medicines in oncology, cardiovascular, and neuroscience, with a history of strategic acquisitions to bolster its pipeline. Recent market activity featured notable volatility following Phase 3 trial disappointments for del-desiran in myotonic dystrophy and pelacarsen in cardiovascular outcomes. These developments prompted a sharp share price decline and subsequent investor discussions regarding acquisition oversight. Earlier positive readouts for remibrutinib in multiple sclerosis provided some offset, yet overall positioning reflected challenges in translating late-stage assets. The stock traded around levels implying a market capitalization near $260-300 billion amid these shifts.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI Trading Bots that trade thousands of different tickers, with only the strongest performers suited to prevailing conditions featured in the trending section. These bots encompass varied trading styles, strategies, timeframes, performance metrics, and ticker sets, allowing users to explore options aligned with specific market dynamics. Available statistics often include ranges of returns, win rates, and drawdown profiles across different market regimes. Review the Trending AI Robots section for detailed, up-to-date bot profiles and performance data.
Head-to-Head Comparison
Johnson & Johnson and Novartis both emphasize pharmaceutical innovation yet differ in scale and diversification. JNJ maintains broader MedTech integration alongside drug development, providing multiple revenue levers, while NVS centers more exclusively on targeted small-molecule and biologic therapies. Recent momentum favored JNJ through incremental regulatory and data successes, contrasting with NVS’s exposure to binary clinical outcomes that amplified price swings. Risk factors include regulatory and litigation elements for both, though NVS encountered heightened M&A-related scrutiny. Sector exposure overlaps in core therapeutic areas, but market sentiment positioned JNJ as comparatively defensive amid the observed period.
Tickeron AI Verdict
Based on observable factors such as trend consistency, pipeline stability indicators, and relative positioning in recent market activity, Tickeron’s AI would currently assign a higher probabilistic preference to JNJ over NVS. This reflects stronger continuity in positive developments and lower recent volatility compared to the clinical setbacks influencing the latter. The assessment remains probabilistic and tied to available data patterns rather than definitive forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and NVS is a Buy.
JNJ | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 11 | |
SMR RATING 1..100 | 37 | 33 | |
PRICE GROWTH RATING 1..100 | 50 | 56 | |
P/E GROWTH RATING 1..100 | 10 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 45 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as JNJ (12). This means that NVS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as NVS (11). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that NVS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as NVS (56). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
JNJ's P/E Growth Rating (10) in the Pharmaceuticals Major industry is in the same range as NVS (22). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
| JNJ | NVS | |
|---|---|---|
| RSI ODDS (%) | 6 days ago 29% | 3 days ago 38% |
| Stochastic ODDS (%) | 3 days ago 49% | 3 days ago 41% |
| Momentum ODDS (%) | 3 days ago 45% | 3 days ago 48% |
| MACD ODDS (%) | 3 days ago 39% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 47% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 44% | 3 days ago 40% |
| Advances ODDS (%) | 3 days ago 47% | 3 days ago 54% |
| Declines ODDS (%) | 5 days ago 40% | 19 days ago 43% |
| BollingerBands ODDS (%) | 3 days ago 45% | 3 days ago 33% |
| Aroon ODDS (%) | 3 days ago 46% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).
- JNJ’s TA Score: 4 bullish, 4 bearish.
- NVS’s TA Score: 4 bullish, 5 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +0.46% price change this week, while NVS (@Pharmaceuticals: Major) price change was +3.63% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.05%. For the same industry, the average monthly price growth was -5.35%, and the average quarterly price growth was +17.52%.
Reported Earning Dates
JNJ is expected to report earnings on Oct 13, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.05% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.